These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15317808)

  • 41. Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy.
    Chen CS; Chen WN; Zhou M; Arttamangkul S; Haugland RP
    J Biochem Biophys Methods; 2000 Mar; 42(3):137-51. PubMed ID: 10737220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subsite preferences of pepstatin-insensitive carboxyl proteinases from prokaryotes: kumamolysin, a thermostable pepstatin-insensitive carboxyl proteinase.
    Oda K; Ogasawara S; Oyama H; Dunn BM
    J Biochem; 2000 Sep; 128(3):499-507. PubMed ID: 10965051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pepstatin-insensitive carboxyl proteinases.
    Oda K; Takahashi S; Shin T; Murao S
    Adv Exp Med Biol; 1995; 362():529-42. PubMed ID: 8540367
    [No Abstract]   [Full Text] [Related]  

  • 44. Free-energy analysis of enzyme-inhibitor binding: aspartic proteinase-pepstatin complexes.
    Kalra P; Das A; Jayaram B
    Appl Biochem Biotechnol; 2001; 96(1-3):93-108. PubMed ID: 11783905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and biological activity of new conformationally restricted analogues of pepstatin.
    Szewczuk Z; Rebholz KL; Rich DH
    Int J Pept Protein Res; 1992; 40(3-4):233-42. PubMed ID: 1478780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease.
    Evin G; Sharples RA; Weidemann A; Reinhard FB; Carbone V; Culvenor JG; Holsinger RM; Sernee MF; Beyreuther K; Masters CL
    Biochemistry; 2001 Jul; 40(28):8359-68. PubMed ID: 11444983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NMR study of the inhibition of pepsin by glyoxal inhibitors: mechanism of tetrahedral intermediate stabilization by the aspartyl proteases.
    Cosgrove S; Rogers L; Hewage CM; Malthouse JP
    Biochemistry; 2007 Oct; 46(39):11205-15. PubMed ID: 17824620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kinetic study on the interaction of Rhizopus chinensis aspartic protease with Streptomyces pepsin inhibitor (acetylpepstatin).
    Nakatani H; Hiromi K; Kitagishi K
    Arch Biochem Biophys; 1988 Jun; 263(2):311-4. PubMed ID: 3288122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
    Pranav Kumar SK; Kulkarni VM
    Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
    Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
    Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors.
    Suguna K; Padlan EA; Bott R; Boger J; Parris KD; Davies DR
    Proteins; 1992 Jul; 13(3):195-205. PubMed ID: 1603809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative pepstatin inhibition studies on individual human pepsins and pepsinogens 1,3 and 5(gastricsin) and pig pepsin A.
    Roberts NB; Taylor WH
    J Enzyme Inhib Med Chem; 2003 Jun; 18(3):209-17. PubMed ID: 14506911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of xyloglucanase from an alkalothermophilic Thermomonospora sp. by a peptidic aspartic protease inhibitor from Penicillium sp. VM24.
    Menon V; Rao M
    Bioresour Technol; 2012 Nov; 123():390-9. PubMed ID: 22940347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin.
    Fujimoto Z; Fujii Y; Kaneko S; Kobayashi H; Mizuno H
    J Mol Biol; 2004 Aug; 341(5):1227-35. PubMed ID: 15321718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of factor Xa by a peptidyl-alpha-ketothiazole involves two steps. Evidence for a stabilizing conformational change.
    Betz A; Wong PW; Sinha U
    Biochemistry; 1999 Nov; 38(44):14582-91. PubMed ID: 10545181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two-step binding mechanism for HIV protease inhibitors.
    Furfine ES; D'Souza E; Ingold KJ; Leban JJ; Spector T; Porter DJ
    Biochemistry; 1992 Sep; 31(34):7886-91. PubMed ID: 1510976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of the interaction between the aspartic peptidase inhibitor SQAPI and aspartic peptidases using surface plasmon resonance.
    Farley PC; Christeller JT; Sullivan ME; Sullivan PA; Laing WA
    J Mol Recognit; 2002; 15(3):135-44. PubMed ID: 12203839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of human cathepsin D with the inhibitor pepstatin.
    Knight CG; Barrett AJ
    Biochem J; 1976 Apr; 155(1):117-25. PubMed ID: 938470
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
    Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
    J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding the structural basis for substrate and inhibitor recognition in eukaryotic GH11 xylanases.
    Vardakou M; Dumon C; Murray JW; Christakopoulos P; Weiner DP; Juge N; Lewis RJ; Gilbert HJ; Flint JE
    J Mol Biol; 2008 Feb; 375(5):1293-305. PubMed ID: 18078955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.